Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications...

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Cancer treatment has shifted towards novel targeted therapies.
• These therapies offer life-saving options but carry risks of cardiotoxicity, specifically QT interval prolongation.
• Adverse drug reactions (ADRs) may not be fully disclosed on initial drug safety labels.

Purpose of the Study:

• To review mechanisms of drug-induced QT interval prolongation.
• To identify anticancer-targeted therapies associated with this adverse event, focusing on tyrosine kinase inhibitors.
• To discuss risk stratification, prevention, and management strategies for cancer patients.

Main Methods:

• Review of mechanisms of QT prolongation.
• Analysis of drug safety data, including the VigiBase® global adverse drug reaction database.
• Discussion of clinical management, drug-drug interactions, and electrocardiographic monitoring.

Main Results:

• Targeted anticancer therapies, particularly tyrosine kinase inhibitors, are frequently associated with QT prolongation.
• Post-marketing surveillance data reveal significant and potentially fatal ADRs not always present on initial labels.
• Drug-drug interactions with supportive care medications (antimicrobials, psychotropics, antiemetics) exacerbate arrhythmic risk.

Conclusions:

• Cancer patients receiving targeted therapies are at risk for QT prolongation and arrhythmias.
• Comprehensive risk assessment, vigilant monitoring, and management of drug interactions are crucial.
• An electrocardiographic QT monitoring algorithm is proposed for patient management.